A nucleosome is the basic unit of DNA packaging. It consists of a segment of DNA wound around a core (“octamer”) of 8 histone proteins (two each of histones H2A, H2B, H3, and H4). The “tails” of these histone proteins stick out, where they can be modified by a number of different histone acetyltransferases, methyltransferases, PARPs, and other epigenetic enzymes. Many of these enzymes modify very specific sites e.g. EZH2, specifically tri-methylates the lysine at position 27 in the H3 histone.

AMSBIO's new line of biotinylated histone peptides have been developed for enzyme kinetic studies as well as for screening small molecular inhibitors of different histone methyltransferases in drug discovery and HTS applications.

The major difference between AMSBIO recombinant nucleosomes made in E. coli and those purified from whole cells is that the recombinant ones are unmodified. E. coli and other bacteria do not have the enzymes to methylate or acetylate the histone proteins. AMSBIO nucleosomes purified from mammalian cells are supplied methylated or acetylated on most histone sites, making them suitable substrates for demethylases.

For further information on the complete range of nucleosomes and histones available from AMSBIO please visit www.amsbio.com/Nucleosomes-and-Histone-Proteins.aspx or contact AMSBIO now on +44-1235-828200 / +1-949-768-8365 or email info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.